The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Oversees the safety pharmacology and toxicology studies including protocol design, advises and directs the execution, data interpretation, and review of reports for new therapeutic entities of various modalities (small molecules, large molecules, peptide conjugates, oligonucleotides, and gene therapies).